Nikhil Duseja

Dr. Nikhil Duseja

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
IAIrfan Ahsan
Irfan Ahsan
HHHussam Al Hennawi
Hussam Al Hennawi
ABAngad Bedi
Angad Bedi
MKMuhammad Khuzzaim Khan
Muhammad Khuzzaim Khan
NDNikhil Duseja
Nikhil Duseja
RHReginald T. Ho
Reginald T. Ho
Background: Left bundle branch area pacing (LBBAP) is a new technique for patients with atrioventricular block (AVB) and preserved left ventricular ejection fraction (LVEF), potentially offering better cardiac function than right ventricular pacing (RVP).Methods: We searched databases and registries for studies that compared LBBAP with RVP in patients with AVB and preserved LVEF. We extracted data on various outcomes and pooled the effect estimates using random‐effects models.Results: Our meta‐analysis included 14 studies (10 observational and 4 RCTs) involving 3062 patients with AVB. The analysis revealed that the QRS duration was significantly shorter in the LBBAP group compared to the RVP group [MD = −35.56 ms; 95% CI: (−39.27, −31.85), p < 0.00001]. Patients in the LBBAP group also exhibited a significant increase in left ventricular ejection fraction (LVEF) [MD = 5.48%; 95% CI: (4.07%, 6.89%), p < 0.00001], and a significant reduction in left ventricular end‐diastolic diameter (LVEDD) compared to RVP [MD = −3.98 mm; 95% CI: (−5.88, −2.09 mm), p < 0.0001]. In terms of clinical outcomes, LBBAP was associated with a significantly lower risk of heart failure hospitalizations (HFHs) compared to RVP [OR = 0.26; 95% CI: (0.16, 0.44), p < 0.0001]. However, no significant differences were observed between the two groups in the implant success rate, pacing impedance, or pacing threshold. The RVP group demonstrated a significantly higher R‐wave amplitude increase than the LBBAP group [MD = 0.85 mV; 95% CI: (0.23, 1.46), p = .007]. Lastly, there was no significant difference in the incidence of complications between the two groups [OR = 2.12; 95% CI: (0.29, 15.52), p = 0.46].Conclusion: LBBAP outperforms RVP in several cardiac function indicators, suggesting it may be a superior pacing method for AVB patients with preserved LVEF. However, the small sample size in studies and the result in heterogeneity call for more research to validate these findings and assess LBBAP's long‐term effects.

7 August 2026 in Medicine
Verified
Journal Article
Open access
RHRaymond Haward
Raymond Haward
NDNikhil Duseja
Nikhil Duseja
HHHet Hirpara
Het Hirpara
HSHarkanwar Sandhu
Harkanwar Sandhu
SKSwathi Deepak Kulkarni
Swathi Deepak Kulkarni
JMJai Kumar Rajavoor Muniswamy
Jai Kumar Rajavoor Muniswamy
Portal hypertension is a central driver of morbidity and mortality in advanced chronic liver disease, yet its contribution to death is frequently underestimated owing to underreporting on death certificates. Population-level data on portal hypertension-related mortality trends and disparities in the United States remain limited. We conducted a retrospective, population-based mortality study using the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Multiple Cause of Death database, identifying deaths with International Statistical Classification of Diseases and Related Health Problems, 10th Revision code K76.6 listed in any cause-of-death field from 1999 to 2023. Crude and age-adjusted mortality rates per 100,000 population were calculated and stratified by sex, U.S. Census region, race/ethnicity, and urban–rural status (the latter restricted to 1999–2020 due to data availability). Temporal trends were assessed using Joinpoint regression, with annual percent change (APC) reported as the primary trend metric and 95% confidence intervals presented for all estimates. A total of 34,551 portal hypertension-related deaths were identified. Overall age-adjusted mortality rates declined sharply from 1999 to 2002 (APC − 12.85%), plateaued for more than a decade, and rose thereafter. Mortality increased significantly in women after 2009 (APC + 6.69%) and in men after 2013 (APC + 6.18%). Among racial and ethnic groups, Hispanic or Latino individuals consistently demonstrated the highest mortality burden throughout the study period, followed by White individuals, whereas Black or African American individuals exhibited comparatively lower but significantly rising rates from 2006 onward. White individuals demonstrated the steepest recent acceleration, with a significant increase after 2014 (APC + 8.51%). Regionally, the South experienced the steepest post-2013 increase, while the Northeast retained the lowest absolute rates despite a significant rise after 2014. Urban populations showed early improvement through 2014 followed by rising mortality, whereas rural populations experienced a later but steeper rise beginning around 2013, with widening urban–rural disparities over time. Portal hypertension-related mortality has risen significantly since the mid-2010s across all demographic and geographic subgroups, with disproportionate burdens among Hispanic individuals, men, rural populations, and residents of the Southern United States. These findings highlight the urgent need for targeted prevention strategies, equitable access to hepatology care, and aggressive management of metabolic and alcohol-related risk factors to reverse this trajectory.

22 April 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
PLPriyanka Mohan Lal
Priyanka Mohan Lal
HMHeema Madhumal
Heema Madhumal
MSMuhammad Hamza Siddiqui
Muhammad Hamza Siddiqui
SPSyed Shahrukh Parvez
Syed Shahrukh Parvez
MHMustafa Ashiq Husain
Mustafa Ashiq Husain
UTUsha Tejwaney
Usha Tejwaney
Celiac disease (CD) and Budd–Chiari syndrome (BCS) are distinct medical conditions affecting different organ systems. However, reports suggest a potential association between them. This review examines existing literature and summarizes the current knowledge regarding the connection between CD and BCS. The pathophysiology of both conditions involves immune dysregulation and prothrombotic tendencies, though through different mechanisms. Several case reports and small studies indicate an increased incidence of BCS in individuals with CD, but the underlying mechanisms remain unclear. Proposed hypotheses include chronic inflammation, hypercoagulability, and potential genetic factors. However, more robust studies are needed to establish a definitive association and elucidate the shared pathophysiological factors between the two conditions. Management of CD primarily involves strict adherence to a gluten-free diet, leading to symptom improvement and normalization of serological markers. BCS requires a stepwise approach involving anticoagulation, endovascular therapy, and, in severe cases, liver transplantation. Recognizing the potential implications of the coexistence of CD and BCS is crucial for developing appropriate management strategies. Further research is warranted to investigate the potential association between CD and BCS, including large-scale epidemiological studies, genetic analyses, and mechanistic investigations. Understanding the underlying mechanisms and identifying risk factors for BCS development in individuals with CD will contribute to enhanced diagnostic capabilities, refined management strategies, and improved patient outcomes.

20 December 2024 in Research Square
Verified
Preprint
Open access
PDF file
NDNikhil Duseja
Nikhil Duseja
KMKanzul Eman Maryam
Kanzul Eman Maryam
GAGhufran Azam
Ghufran Azam
MUMuhammad Uzair
Muhammad Uzair
DADanish Ali Ashraf
Danish Ali Ashraf
MKMaha Mushtaq Khosa
Maha Mushtaq Khosa
Background Pancreatic cancer is 8th most prevalent cancer in the United States with a very high mortality rate. Understanding the epidemiology of Pancreatic cancer is important in identifying the causes and developing preventive strategies. Methodology: Data from the death certificates spanning from 1999–2020, sourced from CDC WONDER (Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research) was analyzed. To quantify national annual trends in pancreatic cancer-related mortality, the Joinpoint Regression Program was used to determine the annual percent change (APC) with 95% CI in age-adjusted mortality rates (AAMRs) per 100,000 people for all ages stratified by year, gender and regions. Results Pancreatic neoplasm claimed about 847,589 lives across all age groups in the US from 1999–2000. The AAMR for pancreatic cancer peaked at 2020 with 11.7 [APC 0.2275 95% CI: 11.6–11.8]. The AAMR for pancreatic cancer-related deaths was 11(95%CI: 10.9 = 11.1) in 2003 and it increased to 11.3(95%CI: 11.2–11.3) in 2006 (APC 0.87* 95%CI: 11.2–11.4). Men had consistently higher AAMRs than women across all age groups throughout the study period of 1999–2000 (overall AAMR men: 13.2 (95% CI: 13.1–13.2); overall AAMR women: 9.9 (95% CI: 9.9–10)). Geographically; the lowest mortality was displayed by the Western regions (AAMR 10.5, 95% CI: 10.2–10.7), followed by Southern (AAMR 11.1, 95%CI: 10.9–11.4), followed by Midwestern (AAMR 11.7, 95%CI: 10.9–11.4), followed by Northeast region (AAMR 11.9, 95%CI: 11.6–12.1) Conclusion We observed an overall annual increase in mortality trends related to pancreatic cancer especially in men and certain regions like Northeast region of the United States. These results emphasize the immediate necessity for a comprehensive strategy to address this lethal illness, encompassing breakthroughs in medical research, focused public health initiatives, and extensive governmental reforms.

AKAnwar Khedr
Anwar Khedr
EHEsraa Hassan
Esraa Hassan
RARida Asim
Rida Asim
MKMuhammad Khuzzaim Khan
Muhammad Khuzzaim Khan
NDNikhil Duseja
Nikhil Duseja
BBBrian Bartlett
Brian Bartlett
Introduction: This study evaluated the impact of parallel-level patient transfers on bed utilization efficiency within the Mayo Clinic Health System in Southern Minnesota, focusing on optimizing resources across tertiary and critical access hospitals. Methods: A retrospective analysis of 179,066 Emergency Department visits (2018–2022) was conducted, with ~2% involving parallel-level transfers for observation or admission. Machine learning was utilized to identify patients suitable for parallel transfers based on demographics, comorbidities, and clinical factors. A Random Forest model with an AUROC of 0.87 guided transfer decisions. Saved patient days were calculated as the difference between the actual LOS and the benchmark LOS based on Diagnosis-Related Groups (DRGs). Generalized estimating equations analyzed length of stay (LOS) differences, adjusted for confounders, with 95% confidence intervals (CI). Statistical analyses were conducted using SPSS (v.26). Results: The mean patient age was 56 years (SD = 17.2), with 51.4% being female. Saved patient days increased from ~600 to 5200 days over the study period. Transferred patients had a 5.7% longer unadjusted LOS compared to non-transferred patients (95% CI: 2.9–8.6%, p < 0.001). After adjustment for demographics and comorbidities, the LOS difference was not significant (adjusted mean difference: 0.4%, 95% CI: −1.7–2.5%, p = 0.51). Conclusions: Parallel-level transfers increased saved patient days, reflecting enhanced resource utilization. However, the adjusted LOS differences were not significant, highlighting the need for robust transfer protocols and controlled studies to confirm these findings.

18 September 2026 in Medicine
Verified
Journal Article
Open access
RHRaymond Haward
Raymond Haward
NDNikhil Duseja
Nikhil Duseja
HSHarkanwar Sandhu
Harkanwar Sandhu
SBShankar Biswas
Shankar Biswas
JMJai Kumar Rajavoor Muniswamy
Jai Kumar Rajavoor Muniswamy
SKSwathi Deepak Kulkarni
Swathi Deepak Kulkarni
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α-synuclein aggregation, resulting in motor dysfunction and increasing mortality. Chronic kidney disease (CKD), affecting nearly 700 million people worldwide, is associated with systemic inflammation, vascular dysfunction, and excess mortality. Emerging evidence suggests a bidirectional relationship between CKD and PD, with renal impairment potentially accelerating neurodegeneration and worsening clinical outcomes. This study examined national mortality trends among individuals with coexisting PD and CKD in the United States from 1999 to 2023. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Mortality data were obtained from the CDC WONDER database. Deaths listing both PD (International Classification of Diseases, Tenth Revision [ICD-10]: G20) and CKD (ICD-10: N18) were identified. Age-adjusted mortality rates (AAMRs) per 1,00,000 population were standardized to the 2000 US population and stratified by year, sex, region, and urban-rural status. Joinpoint regression estimated Annual percent change (APC), with P < .05 considered statistically significant. Between 1999 and 2023, 20,437 deaths were attributed to coexisting PD and CKD. National AAMR increased more than 4-fold, from 0.1 to 0.5 per 1,00,000 (APC = 5.23; 95% CI: 3.92–6.55). Mortality increased in females (0.1–0.3; APC = 5.15; 95% CI: 3.35–6.99) and males (0.2–0.8; APC = 4.79; 95% CI: 3.57–6.02). All census regions demonstrated significant increases, with the greatest rise in the West (APC = 5.92; 95% CI: 4.22–7.64). Mortality also increased in both urban (APC = 5.01) and rural (APC = 4.78) populations. Mortality among individuals with coexisting PD and CKD has risen substantially across demographic and geographic groups in the United States over the past 2 decades. These findings highlight the need for integrated neurology-nephrology care, early recognition of renal dysfunction, and targeted risk-factor management. Further research is warranted to clarify underlying mechanisms and develop strategies to reduce mortality in this high-risk population.